Southwest Airlines Has $11 Million Fine Waived as USDOT Cites Operational Improvements 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
Allegiant Air Faces Union Block in Bid for Foreign Pilots’ Green Cards Amid Staffing Challenges 
Waymo Issues Recall After Reports of Self-Driving Cars Illegally Passing School Buses in Texas 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Netflix’s $72 Billion Warner Bros Discovery Deal Reshapes the Entertainment Landscape 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
SpaceX CEO Elon Musk Denies Reports of $800 Billion Valuation Fundraise 
Boeing Acquisition of Spirit AeroSystems Could Close Soon Amid Ongoing Conditions 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Spirit Airlines Reverses Pilot Furlough Plans Amid Updated Staffing Outlook 
Visa to Move European Headquarters to London’s Canary Wharf 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
